Trial Condition(s):
Contraception, Ovulation inhibition, Contraceptives, Oral
Study to compare cycle control and safety of the oral contraceptive SH T 00186 D (0.02 mg Ethinylestradiol and 3 mg Drospirenone) in a 21-day regimen vs. Mercilon®
Bayer Identifier:
90369
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
Please see attached Study Results Summary below.
Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
441
Trial Dates
Phase
3
Could I receive a placebo?
No
Products
Yasminelle (EE20/DRSP, BAY86-5300)
Accepts Healthy Volunteers
N/A
Where to Participate
Locations
| Locations |
|---|
Trial Design
Multi-center, open, randomized, parallel group comparison of cycle control and safety of the oral contraceptive SH T 00186 D (Ethinylestradiol-ß-Cyclodextrin Clathrate (equivalent to 0.02 mg ethinylestradiol) and 3 mg drospirenone) in a 21-day regimen vs. Mercilon® for 7 cycles in 400 healthy female volunteers
Trial Type:
Interventional
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
N/A
Primary Outcome
- Timeframe:
Secondary Outcome
- Timeframe:
Additional Information
Copyright © Bayer
Powered by
